ASCO 2021 | Breast cancer advances in 2021
Guy Jerusalem, MD, PhD, Domaine Universitaire du Sart Tilman, Liège, Belgium, shares exciting upcoming developments in the breast cancer field. Dr Jerusalem highlights antibody-drug conjugates (ADCs) and immunotherapies as major areas of interest where lots of promising data is expected in the coming years. Further research will clarify optimal targets for ADCs, as well as the best way to combine immunotherapies for maximal patient responses. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Dr. Jerusalem reports personal fees and non-financial support from Novartis, during the conduct of the study: grants, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from Roche, grants, personal feed and non-financial support from Pfizer, personal fees and non-financial support from Lilly, personal fees and non-financial support from Amgen, personal fees and non-financial support from BMS, personal feed and non-financial support from Astra-Zeneca, personal fees from Daiichi Sankyo, personal fees from Abbvie, non-financial support from Medimmune, non-financial support from MerckKGaA.
